Section of Developmental Endocrinology and Biology, Yale Pediatric Thyroid Center, Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, United States of America.
PLoS One. 2012;7(4):e35213. doi: 10.1371/journal.pone.0035213. Epub 2012 Apr 18.
Hyperthyroidism during pregnancy is treated with the antithyroid drugs (ATD) propylthiouracil (PTU) and methimazole (MMI). PTU currently is recommended as the drug of choice during early pregnancy. Yet, despite widespread ATD use in pregnancy, formal studies of ATD teratogenic effects have not been performed.
We examined the teratogenic effects of PTU and MMI during embryogenesis in mice. To span different periods of embryogenesis, dams were treated with compounds or vehicle daily from embryonic day (E) 7.5 to 9.5 or from E3.5 to E7.5. Embryos were examined for gross malformations at E10.5 or E18.5 followed by histological and micro-CT analysis. Influences of PTU on gene expression levels were examined by RNA microarray analysis.
When dams were treated from E7.5 to E9.5 with PTU, neural tube and cardiac abnormalities were observed at E10.5. Cranial neural tube defects were significantly more common among the PTU-exposed embryos than those exposed to MMI or vehicle. Blood in the pericardial sac, which is a feature indicative of abnormal cardiac function and/or abnormal vasculature, was observed more frequently in PTU-treated than MMI-treated or vehicle-treated embryos. Following PTU treatment, a total of 134 differentially expressed genes were identified. Disrupted genetic pathways were those associated with cytoskeleton remodeling and keratin filaments. At E 18.5, no gross malformations were evident in either ATD group, but the number of viable PTU embryos per dam at E18.5 was significantly lower from those at E10.5, indicating loss of malformed embryos. These data show that PTU exposure during embryogenesis is associated with delayed neural tube closure and cardiac abnormalities. In contrast, we did not observe structural or cardiac defects associated with MMI exposure except at the higher dose. We find that PTU exposure during embryogenesis is associated with fetal loss. These observations suggest that PTU has teratogenic potential.
怀孕期间的甲状腺功能亢进症用抗甲状腺药物(ATD)丙基硫氧嘧啶(PTU)和甲巯咪唑(MMI)治疗。PTU 目前被推荐为早孕时的首选药物。然而,尽管在怀孕期间广泛使用 ATD,但尚未进行 ATD 致畸作用的正式研究。
我们在小鼠胚胎发生过程中检查了 PTU 和 MMI 的致畸作用。为了涵盖胚胎发生的不同时期,从胚胎期(E)7.5 至 9.5 或从 E3.5 至 E7.5 每天用化合物或载体处理母体。在 E10.5 或 E18.5 检查胚胎的大体畸形,然后进行组织学和微 CT 分析。通过 RNA 微阵列分析检查 PTU 对基因表达水平的影响。
当母体从 E7.5 至 E9.5 用 PTU 处理时,在 E10.5 时观察到神经管和心脏异常。与暴露于 MMI 或载体的胚胎相比,暴露于 PTU 的胚胎中颅神经管缺陷更为常见。心包中的血液,这是异常心脏功能和/或异常血管的特征,在 PTU 处理的胚胎中比 MMI 处理的胚胎更频繁地观察到。PTU 处理后,共鉴定出 134 个差异表达基因。破坏的遗传途径与细胞骨架重塑和角蛋白丝有关。在 E18.5 时,在任何 ATD 组中均未出现明显的大体畸形,但 E18.5 时每只母体的存活 PTU 胚胎数量明显低于 E10.5 时的数量,表明畸形胚胎丢失。这些数据表明,胚胎发生期间的 PTU 暴露与神经管闭合延迟和心脏异常有关。相比之下,我们没有观察到与 MMI 暴露相关的结构或心脏缺陷,除非在更高剂量下。我们发现胚胎发生期间的 PTU 暴露与胎儿丢失有关。这些观察结果表明 PTU 具有致畸潜力。